BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology,…
FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approvalCompany…
-- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two…
Focal One Robotic HIFU procedure now covered under France’s national universal health systemReimbursement milestone allows increased patient access to Focal One…
Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new FDA…
In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo…
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…
Chemotherapy-free combination regimen has the potential to usher in new era for first-line treatment, with median overall survival projected to…
No-cost access available to qualified researchers via open-source federated data platformSAN FRANCISCO, Sept. 06, 2025 (GLOBE NEWSWIRE) -- 23andMe Research…
After decades of outreach and evidence—never refuted—it is urgent to fund two 3D-CBS devices that could halve cancer deaths, and…